$9.56
7.90% yesterday
Nasdaq, Nov 07, 10:00 pm CET
ISIN
US30068X1037
Symbol
XGN

Exagen Inc Stock price

$9.56
-1.40 12.77% 1M
+2.73 39.97% 6M
+5.46 133.17% YTD
+6.96 267.69% 1Y
+7.17 300.00% 3Y
-5.99 38.52% 5Y
-9.02 48.55% 10Y
-9.02 48.55% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
-0.82 7.90%
ISIN
US30068X1037
Symbol
XGN
Industry

Key metrics

Basic
Market capitalization
$235.2m
Enterprise Value
$228.2m
Net debt
positive
Cash
$30.0m
Shares outstanding
22.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.0 | 3.5
EV/Sales
3.9 | 3.3
EV/FCF
negative
P/B
11.2
Financial Health
Equity Ratio
21.4%
Return on Equity
-158.4%
ROCE
-29.0%
ROIC
-55.9%
Debt/Equity
1.1
Financials (TTM | estimate)
Revenue
$58.9m | $68.2m
EBITDA
$-12.3m | $-6.1m
EBIT
$-14.0m | $-10.4m
Net Income
$-17.0m | $-14.9m
Free Cash Flow
$-16.0m
Growth (TTM | estimate)
Revenue
3.9% | 22.5%
EBITDA
10.9% | 48.7%
EBIT
11.2% | 23.9%
Net Income
1.9% | 1.3%
Free Cash Flow
-151.3%
Margin (TTM | estimate)
Gross
59.4%
EBITDA
-20.9% | -9.0%
EBIT
-23.9%
Net
-28.9% | -21.9%
Free Cash Flow
-27.2%
More
EPS
$-0.8
FCF per Share
$-0.7
Short interest
4.4%
Employees
212
Rev per Employee
$260.0k
Show more

Is Exagen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Exagen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Exagen Inc forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Exagen Inc forecast:

Buy
92%
Hold
8%

Financial data from Exagen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
59 59
4% 4%
100%
- Direct Costs 24 24
3% 3%
41%
35 35
4% 4%
59%
- Selling and Administrative Expenses 43 43
3% 3%
73%
- Research and Development Expense 5.90 5.90
25% 25%
10%
-12 -12
11% 11%
-21%
- Depreciation and Amortization 1.74 1.74
13% 13%
3%
EBIT (Operating Income) EBIT -14 -14
11% 11%
-24%
Net Profit -17 -17
2% 2%
-29%

In millions USD.

Don't miss a Thing! We will send you all news about Exagen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exagen Inc Stock News

Neutral
Seeking Alpha
4 days ago
Exagen Inc. ( XGN ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Ryan Douglas - Investors Relations Officer John Aballi - CEO, President & Director Jeffrey Black - CFO & Corporate Secretary Conference Call Participants Anderson Schock - B. Riley Securities, Inc., Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Vidyun Bais - BTIG, LLC, Resear...
Neutral
GlobeNewsWire
4 days ago
CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates.
Neutral
GlobeNewsWire
16 days ago
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology's (ACR) annual meeting, ACR Convergence 2025, being held October 24-29, 2025, at the McCormick Place Convention Center in Chicago, Illinois.
More Exagen Inc News

Company Profile

Exagen, Inc. is a commercial-stage diagnostics company. It engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company operates under the Avise brand. Exagen was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Head office United States
CEO John Aballi
Employees 212
Founded 2002
Website exagen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today